Adagene Inc

978

Company Profile

  • Business description

    Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

  • Contact

    Xinghu Street, Suzhou Industrial Park
    4th Floor, Building C14, No. 218
    Jiangsu Province
    Suzhou215123
    CHN

    T: +86 51287773632

    https://www.adagene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    138

Stocks News & Analysis

stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.
stocks

ASX listed tariff play

Trump’s focus on US steel production may benefit this firm.
stocks

Ask the analyst: How reliant are Guzman shares on international growth?

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,952.3061.500.69%
CAC 407,822.0099.911.29%
DAX 4024,370.93361.551.51%
Dow JONES (US)44,484.49229.710.52%
FTSE 1008,972.6446.090.52%
HKSE24,789.67290.721.19%
NASDAQ20,885.65155.160.75%
Nikkei 22539,815.4885.71-0.21%
NZX 50 Index12,896.848.57-0.07%
S&P 5006,297.3633.660.54%
S&P/ASX 2008,701.5062.500.72%
SSE Composite Index3,524.898.060.23%

Market Movers